Patients in the United States who have the cornea-damaging disease keratoconus may soon be able to benefit from a new treatment that is already proving effective in Europe and other parts of the world. The treatment, called collagen crosslinking, improved vision in almost 70 percent of patients treated for keratoconus in a recent three-year clinical trial in Milan, Italy. The treatment is in...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Vitamin B-Based Treatment for Vision-Threatening Corneal Disease May Offer Some Patients a Permanent Solution
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account